Overview

A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics

Status:
Completed
Trial end date:
2019-11-25
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study in rheumatoid arthritis participants inadequately responding to biologics.
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Co., Ltd.
Treatments:
Quetmolimab